The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Copy number aberration burden on circulating tumor DNA predicts recurrence risk after neoadjuvant chemotherapy in patients with triple-negative breast cancer: Post-hoc analysis of phase III PEARLY trial.
 
Min Hwan Kim
Research Funding - AstraZeneca; Daewoong Pharmaceutical
 
Gun Min Kim
No Relationships to Disclose
 
Seul-Gi Kim
No Relationships to Disclose
 
Jin Mo Ahn
Employment - GC Genome
 
Jee Hung Kim
No Relationships to Disclose
 
Jeeye Kim
No Relationships to Disclose
 
Hyung Seok Park
No Relationships to Disclose
 
Seho Park
No Relationships to Disclose
 
Byeong-Woo Park
No Relationships to Disclose
 
Seung Il Kim
No Relationships to Disclose
 
Joon Jeong
No Relationships to Disclose
 
Ji Eun Lee
No Relationships to Disclose
 
Soonmyung Paik
Employment - Theragen Bio
Leadership - Theragen Bio
Stock and Other Ownership Interests - ImmuneOncia
Consulting or Advisory Role - medpacto
 
Sang Woo Kim
No Relationships to Disclose
 
Kyung Hae Jung
Consulting or Advisory Role - AstraZeneca; Bixink; Celgene; Eisai; Everest Medicine; Merck; Novartis; Roche; Takeda
 
Eunhae Cho
Employment - GC Genome
 
Joohyuk Sohn
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Daiichi Sankyo (Inst); GlaxoSmithKline (Inst); Lilly (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); Sanofi (Inst)
Other Relationship - Roche